
Pancreatic Cancer
Latest News
Latest Videos

CME Content
More News

Longer survival rates were experienced by patients receiving chemotherapy both before and after surgery vs only after surgery.

Data from a phase 1 trial may support the utility of IBI343 for patients with advanced pancreatic ductal adenocarcinoma.

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

Higher CA19-9 levels appear to correlate with increased recurrence and mortality for specific patients with pancreatic cancer who undergo surgical resection.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.

A retrospective cohort study from the Trans-Atlantic Pancreatic Surgery Consortium determined a sustained OS rate with modified FOLFIRINIX in patients with pancreatic ductal adenocarcinoma.

Patients with metastatic pancreatic ductal adenocarcinoma may now receive irinotecan liposome in combination with 5-fluorouracil/leucovorin and oxaliplatin in the first-line setting, which has been approved by the FDA.

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.

Treatment with NT-I7 may boost the immune system and enhance antitumor activity in patients with pancreatic cancer and other solid tumors.

Starting April 1, 2024, Diane Simeone will be the new director of UCSD Moores Cancer Center.

Data from a phase 2 trial support the potential survival benefit of CAN-2409 plus prodrug for patients with borderline resectable pancreatic ductal adenocarcinoma.

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.

Developers plan to assess onvansertib plus standard of care as a frontline treatment for patients with metastatic pancreatic ductal adenocarcinoma in an investigator-initiated trial.

LSAM-PTX plus standard of care appears efficacious in a small population of patients with locally advanced pancreatic cancer.



















































